Validation of MdmX as a therapeutic target for reactivating p53 in tumors
about
Chemical Variations on the p53 Reactivation ThemeTumorigenesis promotes Mdm4-S overexpression.Mdm proteins: critical regulators of embry ogenesis and homeostasis.MDM2 oligomers: antagonizers of the guardian of the genome.Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition.MDM2, MDMX and p53 in oncogenesis and cancer therapyRibosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesisTemporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse alleleLimiting the power of p53 through the ubiquitin proteasome pathway.MicroRNA-34a modulates MDM4 expression via a target site in the open reading frameA fluorescent-based high-throughput screening assay for small molecules that inhibit the interaction of MdmX with p53.Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stressThe effect of immunological status, in-vitro treatment and culture time on expression of eleven candidate reference genes in bovine blood mononuclear cells.Sall2 is required for proapoptotic Noxa expression and genotoxic stress-induced apoptosis by doxorubicinTargeting Mdmx to treat breast cancers with wild-type p53.Reversible modulation of SIRT1 activity in a mouse strain.Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cellsThe p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.MDM4 is a key therapeutic target in cutaneous melanoma.MDMX contains an autoinhibitory sequence element.Mdm2 and MdmX as Regulators of Gene ExpressionTargeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.Mouse models of Mdm2 and Mdm4 and their clinical implications.p53 as an intervention target for cancer and aging.Oncoprotein stabilization in brain tumors.Targeting p53-MDM2-MDMX loop for cancer therapy.MDM4 is a rational target for treating breast cancers with mutant p53.The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression.Mouse modelling of the MDM2/MDMX-p53 signalling axis.Pharmacological activation of wild-type p53 in the therapy of leukemia.A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1).MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.Targeting MDM4 Splicing in Cancers.Exploiting the p53 Pathway for Therapy.MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation.BAC transgenic mice provide evidence that p53 expression is highly regulated in vivo.Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.
P2860
Q26749008-F3A04E9B-EC83-4191-8526-79287C4FDA1BQ33688440-FD927976-D3EF-4ABC-8F89-5E5E541BF25EQ33712220-799C1C97-A623-4734-B7A3-390050B80EFEQ33922100-D02A1A28-3554-4BA2-B4D8-7B13EC0485A1Q33998827-02759CBC-7A5E-4762-873B-DC9FC375C10BQ34166049-B5FBEED2-2787-4116-80E6-0F92D9389A18Q34178921-17A60E2F-CCD8-42F4-991F-1E9BCBE88453Q34273969-B1C4144C-D1C8-41F8-8E9F-A1C6CCFC2522Q34342940-5EBD7CEE-B39A-45C2-9674-AC6EDB42EE0CQ34369223-F7200D22-2737-4387-B3B2-65EB4AE5523DQ34418111-A98133E5-0C4F-4B93-A407-F909EAD01DC4Q34989369-5F12AF40-3F6F-4E02-B9F1-C8EB03727E23Q35646655-78A908DF-CFAD-4DF4-A7AC-E48252E7EF43Q36293819-4570B351-0F23-40E2-A3E7-65FAEE0297B0Q36293839-51AE2BF4-E803-44A8-902E-690663DE6715Q36300940-510D3256-B6FD-4BB1-A66E-E1B6C6BC73B2Q36430692-01CF92AE-1DD9-484A-A18F-3F7F12214FEEQ36485161-B739EE12-3A6E-4731-B8F6-51ED5ADB4E3EQ36509629-C5509AA5-B117-4743-A133-8A9D3D066A42Q37096987-9292BDB1-037B-4620-89D5-934B01ABFDF8Q37276522-A355D7B2-8B28-435B-8FEE-604604531E3CQ38059700-038CAF31-372F-4200-8C7D-61F64A56753CQ38059739-61C652E6-7E2D-4A7C-B32A-0C4534C31618Q38074740-93FAB02F-2657-4E20-8068-77F740F97354Q38152454-7EECD9C2-51EE-439A-B1A0-D541195A3D28Q38156100-B6E098AF-3C67-4427-B0AC-D431EFDC104EQ38247168-B377F88B-93A4-432D-A4D1-500E87B42EDCQ38720844-38B4E7F0-B251-41BA-A323-E7A38CEF6DD0Q38756911-34115B54-3A6F-4B87-8033-DEC306051486Q38769323-87658299-B8E5-4515-9112-982FF180ABF3Q38872029-B756C393-0557-44EB-9363-2ED4DA0C49B9Q38878220-2AC15EC0-4367-4AF0-8A7C-2F9866DC7EC6Q38884006-2042193F-1474-4EFC-8A9C-C1FDD2AA6D74Q38946224-DD8088E9-D063-4F66-ABEA-524FA4D39466Q39134087-2DE79600-5F99-4436-B3BE-A9C47847A214Q39404029-66ED0ED9-A81C-4DCD-ADCD-E39A73AE140CQ40363516-835B9215-1BEF-493F-831A-A98C5C6C7B0CQ42156598-F3D80195-291A-4CAA-9B86-EF6FDD2F1A45Q42482469-8855056D-6473-4E52-9781-63B1AB08D7F6Q45246957-09C52518-8393-4127-A4FD-1A30A4505B43
P2860
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@ast
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@en
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@nl
type
label
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@ast
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@en
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@nl
prefLabel
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@ast
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@en
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@nl
P2093
P2860
P356
P1433
P1476
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
@en
P2093
Carla P Martins
Daniel Garcia
Emmanuelle Passegué
Gerard I Evan
Lamorna Brown Swigart
Matthew R Warr
P2860
P304
P356
10.1101/GAD.16722111
P577
2011-08-01T00:00:00Z